Brief: Cabaletta Bio Receives FDA Clearance Of Ind Application For Caba-201 For Treatment Of Myositis
16/05/2023 12:02
May 16 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO RECEIVES FDA CLEARANCE OF IND APPLICATION
FOR
CABA-201 FOR TREATMENT OF MYOSITIS
* CABALETTA BIO RECEIVES FDA CLEARANCE OF IND APPLICATION
FOR
CABA-201 FOR TREATMENT OF MYOSITIS
Source text for Eikon: ID:nGNX469B8t
Further company coverage: CABA.O
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity